Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 2

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 2
---
    4 |
| Risk Factors                                      |     |    6 |
| Offer Statistics and Expected Timetable           |     |    6 |
| Forward-Looking Statements                        |     |    7 |
| Capitalization                                    |     |    9 |
| Use of Proceeds                                   |     |    9 |
| Description of Share Capital                      |     |   10 |
| Description of Subscription Rights                |     |   21 |
| Description of Warrants                           |     |   22 |
| Description of Units                              |     |   24 |
| Taxation                                          |     |   24 |
| Plan of Distribution                              |     |   24 |
| Legal Matters                                     |     |   28 |
| Experts                                           |     |   28 |
| Where You Can Find More Information               |     |   28 |
| Incorporation of Certain Documents by Reference   |     |   29 |
| Enforceability of Civil Liabilities               |     |   30 |
| Expenses                                          |     |   30 |

<div align='center'>S-i

ABOUT THIS PROSPECTUS SUPPLEMENT</div>

A registration statement on
Form F-3 (File No. 333-275991) utilizing a shelf registration process relating to the securities described in this prospectus supplement
was declared effective on December 26, 2023. Under that shelf registration statement, of which this prospectus supplement is a part, we
may, from time to time, sell up to an aggregate of $50 million of Common Shares, warrants and units. As of November 12, 2025, we have
sold approximately $2.4 million of our securities under that shelf registration statement. We sometimes refer to the Common Shares
as the “securities” throughout this prospectus.

This document contains two
parts. The first part is this prospectus supplement, which describes the terms of this offering of the Common Shares, and also adds, updates
and changes information contained in the accompanying prospectus and the documents incorporated herein and therein by reference. The second
part is the accompanying prospectus, which gives more general information about us, some of which may not apply to this offering. You
should read both this prospectus supplement and the accompanying prospectus, including the information incorporated by reference herein
and therein. To the extent the information contained in this prospectus supplement differs or varies from the information contained in
the accompanying prospectus or any document filed prior